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Background: There is limited evidence regarding the optimal tim-
ing of initiating antiretroviral therapy (ART) in children. We con-
ducted a causal modeling analysis in children ages 1–5 years from 
the International Epidemiologic Databases to Evaluate AIDS West/
Southern-Africa collaboration to determine growth and mortality 
differences related to different CD4-based treatment initiation crite-
ria, age groups, and regions.
Methods: ART-naïve children of ages 12–59 months at enrollment 
with at least one visit before ART initiation and one follow-up visit 
were included. We estimated 3-year growth and cumulative mor-
tality from the start of follow-up for different CD4 criteria using 
g-computation.
Results: About one quarter of the 5,826 included children was from 
West Africa (24.6%).The median (first; third quartile) CD4% at the 
first visit was 16% (11%; 23%), the median weight-for-age z-scores 
and height-for-age z-scores were −1.5 (−2.7; −0.6) and −2.5 (−3.5; 
−1.5), respectively. Estimated cumulative mortality was higher 
overall, and growth was slower, when initiating ART at lower CD4 
thresholds. After 3 years of follow-up, the estimated mortality dif-
ference between starting ART routinely irrespective of CD4 count 
and starting ART if either CD4 count <750 cells/mm3 or CD4% 
<25% was 0.2% (95% CI = −0.2%; 0.3%), and the difference in the 
mean height-for-age z-scores of those who survived was −0.02 (95% 
CI = −0.04; 0.01). Younger children ages 1–2 and children in West 
Africa had worse outcomes.
Conclusions: Our results demonstrate that earlier treatment initia-
tion yields overall better growth and mortality outcomes, although 
we could not show any differences in outcomes between immediate 
ART and delaying until CD4 count/% falls below 750/25%.
(Epidemiology 2016;27: 237–246)
Despite a reduced number of newly infected children in 2012, the burden of HIV remains high with 260,000 new annual 
pediatric infections in low- and middle-income countries.1 The 
optimal timing of antiretroviral treatment (ART) initiation in 
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children beyond 12 months of age remains  controversial: early 
ART initiation may reduce morbidity and mortality but could 
increase the risk of toxicity, complications due to nonadher-
ence, and early development of drug resistance.2–6
The World Health Organization (WHO) 2006 guide-
lines recommended treatment initiation for all children with 
WHO clinical stage III/IV (with exceptions for children 
≥12 months, stage III, and particular clinical events) or based 
on age-dependent CD4 criteria for children with clinical 
stage I/II (starting ART if [1] CD4 count <350 cells/mm3 or 
CD4% <15% for children ages 36–59 months, [2] CD4 count 
<750 cells/mm3 or CD4% <20% for children ages 12–35 
months). The CHER trial showed a 76% (95% CI = 49%, 
89%) reduction in mortality in infants, enrolled at ages 6–12 
weeks, for immediate ART initiation versus deferring ART 
until CD4% was lower than 25%.7 These results caused WHO 
to update their guidelines in 2008 to recommend ART ini-
tiation in all HIV-infected children less than 12 months old, 
regardless of their clinical and immunological status. These 
recommendations were expanded to all HIV-infected children 
less than 24 months old in 2010 while for children between 24 
and 59 months, with an asymptomatic or mild clinical disease, 
ART was recommended if either CD4 count <750 cells/mm3  
or CD4% <25%. Both the 2006 and the 2010 recommen-
dations relied, however, solely on the evaluation of disease 
progression in analyses that were neither randomized experi-
ments nor causally interpretable. In addition, many of these 
analyses were based on data from high-income countries.8–11
The question of when to start was also investigated 
in the PREDICT trial in which Asian children of ages 1–12 
were included at a median age of 6.4 years, with only 6% 
in their second year of life.3,12,13 This trial did not show any 
difference between immediate ART initiation and deferring 
ART until either the CD4% was below 15% or any CDC 
category C event occurred—with respect to mortality and 
morbidity outcomes. The trial did, however, show better 
height gain for children who start ART immediately. How-
ever, the authors suggested that the study was underpowered 
to detect differences due to the lower than expected event 
rate. In Southern African children, a causal modeling study 
showed no mortality difference (MD) in 2- to 5-year-old 
children for starting ART immediately versus starting ART 
when either the CD4 count falls below 750 cells/mm3 or the 
CD4% drops below 25%.14 In 2013, WHO guidelines were 
further updated to recommend ART initiation in all children 
less than 5 years. This change was mainly motivated by 
potential programmatic advantages, i.e., to provide simpli-
fied criteria for initiating ART and to bring young children 
into the health care system.
Thus, there still remain considerable evidence gaps: a 
comparison of different CD4 initiation criteria has never been 
explored for children ages 1–2 years. These children are known 
to have slower disease progression than infants, but also prog-
ress faster than older children and thus findings both from the 
CHER and PREDICT trial, as well from other recent analyses, 
may not apply to them.3,5 Moreover, it is of interest whether the 
evidence for children ages 2–5 years can be generalized to West 
African populations and whether the different growth response 
suggested by the PREDICT trial applies to these populations.
We thus used g-computation14–16 to determine mortality 
and growth differences for different ART initiation strategies 
in young children from West and Southern Africa. We chose 
g-computation because it allows adjustment for time-varying 
confounders affected by prior treatment; in our data, these 
are CD4 count, CD4%, and WHO stage (approximated by 
weight-for-age z-scores [WAZ]), which influence both ART 
initiation and our outcome measures. Traditional multivariate 
regression techniques may yield biased treatment effect esti-
mates. An advantage of g-computation over competing meth-
ods is its suitability to compare dynamic intervention rules, its 
efficiency, and that it provides natural estimation of marginal 
effects.17
Our primary study aims were to (1) compare mortality 
and height outcomes for different CD4-based treatment initia-
tion criteria (derived from selected CD4 criteria from WHO 
guidelines since 2006), (2) contrast mortality and growth of 
1- to 2-year-old children with older children, and (3) inves-
tigate the heterogeneity of results from Southern Africa and 
West Africa. All our estimates are based on the idealized con-
ditions of regular visits (every 3 months) at which CD4 mea-
surements are taken, and instantaneous treatment initiation if 
a treatment threshold has been reached.
METHODS
This study includes data of 16 cohorts from Côte 
d’Ivoire, Burkina Faso, Ghana, Senegal, Togo, South Africa, 
Malawi, and Zimbabwe. All cohorts are part of either the 
IeDEA West Africa or IeDEA Southern Africa cohort col-
laboration. Both collaborations have been described else-
where.18–21 In brief, data were collected at each facility 
as part of routine monitoring and were transferred to the 
coordinating data centers at Bordeaux University, France, 
University of Cape Town, South Africa, and University of 
Bern, Switzerland. All contributing sites obtained ethical 
approval from the relevant local institutions before sub-
mitting anonymized patient data to the collaboration. The 
data centers in Bordeaux, Bern, and Cape Town got ethical 
approval from the respective universities’ review boards to 
analyze these data.
This study is limited to cohorts which routinely capture 
both pre-ART and post-ART data of HIV-infected children. 
All ART naïve children of ages 12–59 months at enrollment 
with at least one visit before ART initiation and one follow-up 
visit were included (Figure 1).
The analysis made use of children’s age at enrollment, 
their sex, treatment facility, date of ART initiation as well as 
CD4 count, CD4%, WAZ, and height-for-age z-scores, both 
at time of enrollment and during follow-up. All z-scores 
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were calculated using WHO standards.22 We defined young 
children to be those who present at ages 12–24 months (1- to 
2-year age group), and old children to be those who present 
at ages >24 months and ≤59 months (2- to 5-year age group). 
Follow-up data was evaluated 1 month after enrollment, 
3 months after enrollment and then subsequently in 3-month 
intervals for a period of up to 3 years. If no data were avail-
able for a particular interval, the data were defined to be 
missing. Children were defined as being lost to follow-up 
(LTFU), and censored, if at the time of database closure 
they had no contact with their health care facility for at least 
9 months since their last recorded visit. In a sensitivity anal-
ysis, we censored children 9 months after having no contact 
with their health care facility, even if they re-entered care 
after 10 months or more.
We carried forward missing CD4 count, CD4%, weight- 
and height-for-age z-score follow-up data and used multiple 
imputation by means of the expectation-maximization-boot-
strap algorithm23 to deal with missing baseline data. The 
imputation model included all baseline variables, follow-
up variables (including lagged and lead versions of them), 
death, a carry-forward indicator variable, and region, and also 
accounted for the longitudinal, possibly nonlinear, structure 
of the data.
We summarized the data at time of enrollment, strati-
fied by age and region, and during follow-up. Continuous data 
were described with medians (reported with first; third quar-
tiles) and categorical data were summarized by proportions.
The primary analysis used g-computation to estimate 
cumulative mortality and growth (mean HAZ of children 
FIGURE 1. 'MPXDIBSUTFMFDUJPOPGQBUJFOUT
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who are alive) during 3 years of follow-up for different 
interventions strategies: (1) immediate ART, (2) delaying 
ART until CD4 fell below750 cells/mm3 or 25%, (3) delay-
ing ART until CD4 fell below 350 cells/mm3 or 15%, or 
(4) no ART given. This analysis emulates the following 
clinical trial: HIV positive and ART-naïve children, ages 
1–5 years, presenting at a health care facility for the first 
time, are randomly assigned one of the four treatment strat-
egies (1)–(4). Each of the four arms is, therefore, differing 
by the CD4 thresholds used to determine the timing of ART 
initiation. Under full adherence to the regime, no admin-
istrative censoring, and no loss to follow-up, we can esti-
mate the cumulative mortality at time t for each of the four 
regimes as well as the growth (mean height-for-age z-score) 
of those children who survived until time t. We assume that 
CD4 count/% is measured and evaluated regularly because 
we are interested in the outcomes that would be observed if 
treatment strategies were followed; we, therefore, evaluate 
the outcomes under an ideal monitoring situation. We report 
cumulative mortality and growth for different follow-up 
times t, together with 95% bootstrap confidence intervals. 
We also report differences between the different interven-
tions, regions, and age groups.
The mean height-for-age z-score was chosen as the 
primary growth outcome to allow comparison with the PRE-
DICT trial.13 Secondary growth outcomes are median height-
for-age z-score, proportion with height-for-age z-score greater 
than −2, and cumulative incidence of attaining height-for-age 
z-score greater than −2 before the competing event of death 
occurs. We estimate all growth outcomes under no administra-
tive censoring, and no loss to follow-up, but allow for death of 
children, which means growth is estimated for children who 
survived until time t.
G-computation has been used before to determine 
the optimal timing of treatment initiation in adults.24,25 
Our implementation of the g-computation algorithm is 
similar to the one described by Westreich et al.24 but dif-
fers slightly from this algorithm in that we use multiple 
imputation for baseline data and other variables, relevant 
to pediatric analyses, are included. To implement g-com-
putation, we had to model (at each time point t) the asso-
ciations of CD4 count, CD4%, weight- and height-for-age 
z-scores, and death with disease progression history (CD4 
count, CD4%, weight- and height-for-age z-scores at time 
t-1), baseline characteristics (CD4 count, CD4%, weight- 
and height-for-age z-scores), demographics (age, sex, 
region), and the intervention (ART at times t-1 and t-2) 
using additive linear and logistic regression models. More 
details about our implementation are listed in eTextbox 2 
(http://links.lww.com/EDE/A987).
We conducted several sensitivity analyses: cumula-
tive mortality was estimated (1) if only children with com-
plete baseline data are included, and (2) if missing follow-up 
data, as well as outcome data of lost children, are imputed 
(eTextbox 1; http://links.lww.com/EDE/A987). Growth was 
estimated (3) if only children with complete baseline data 
are included, and (4) under the assumption of no mortality 
in our population. We also estimated the outcomes and the 
confounders under the natural course, i.e., under no treatment 
intervention, and compared it to the observed data.16,25
In a secondary descriptive analysis, we estimated dis-
ease progression as the probability of falling below a CD4 
value of 750 cells/mm3 or 25% for those children who were 
above this threshold at enrollment. Children LTFU, dead, or 
initiating ART were censored (first analysis) and treated as a 
competing risk (second analysis). Results were summarized 
using the Kaplan–Meier estimator and cumulative incidence 
curves,26 respectively.
RESULTS
Descriptive Results
Among 22,172 children in the database, 7,078 children 
were in the eligible age range from cohorts that capture pre-
ART data. After excluding 258 non-ART naïve children and 
1,264 children with no follow-up, 5,826 were included in 
the analysis, of which 1,434 (24.6%) were from West Africa 
(Figure 1). Median (first; third quartile) follow-up was 27.4 
(8.6; 35.0) months. Of 267 deaths, 158 (59.2%) occurred in 
Southern Africa and 58.8% within the first 6 months. Out of 
1,195 (20.5%) children LTFU, 869 (72.3%) were from South-
ern Africa.
Patient characteristics are summarized in the Table. At pre-
sentation, the median age was 2.6 (1.8; 3.8) years. The median 
CD4 count was 662 cells/mm3 (389; 1,011), the median CD4 per-
cent 16% (11%; 23%), and median height- and weight-for-age 
z-scores were −2.5 (−3.5; −1.5) and −1.5 (−2.7; −0.6), respec-
tively. Almost 75% of children started ART. Characteristics at 
enrollment were similar when comparing 1- to 2-year-old with 
2- to 5-year-old children, although the latter had a slightly better 
weight- and height-for-age z-scores profile. In both regions, there 
was an improvement in median CD4 count/CD4%/weight- and 
height-for-age z-scores over time, all outcomes being slightly 
better in Southern Africa than West Africa except for height-for-
age z-scores (eTable 1, eFigure 1; http://links.lww.com/EDE/
A987). The increase of the mean height-for-age z-score applied 
to children both on ART and not on ART (eFigure 1; http://links.
lww.com/EDE/A987). The proportion of missing data at baseline 
varied from 18.4% for CD4 count to 40.3% for HAZ (Table). 
CD4 count/% was available every 3 months for 18%/15% of 
children; the median availability was every 6 months for CD4 
count and every 8 months for CD4%. 19% (14%) of the 921 
patients who had both a 3 monthly CD4 count and CD4% 
measurement started ART instantaneously given a 750/25% 
(350/15%) threshold.
Progression to CD4 Threshold
The estimated proportion of children who progressed 
to below the threshold of 750 cells/mm3 or 25% was similar 
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in Southern and West Africa throughout follow-up, irrespec-
tive of whether a competing risk approach was used or not 
(Figure 2). After 3 years, 71.6% (95% CI = 64.8%; 78.1%) 
of Southern African children and 74.9% (95% CI = 59.5%; 
87.9%) of West African children were estimated to have pro-
gressed below the threshold (Kaplan–Meier estimator). The 
estimates obtained from the cumulative incidence curves were 
slightly higher (75.7% [69.7%; 81.9%] and 83.6% [68.1%; 
94.4%], respectively).
Mortality Analysis
The estimated cumulative mortality for different treat-
ment strategies is summarized in Figure 3 (top left) and 
eTable2 (http://links.lww.com/EDE/A987). There is a trend 
toward higher mortality associated with starting ART at lower 
CD4 thresholds during the whole follow-up period. After 
3 years of follow-up, mortality for the different strategies was 
estimated to be 8.8% (7.7%; 11.1%; no ART), 5.7% (5.0%; 
6.6%; ART if CD4 <350/15%), 5.0% (4.3%; 5.9%; ART if 
CD4 <750/25%), and 4.8% (4.3%; 5.9%; immediate ART). 
The estimated MD between the latter two strategies was 0.2% 
(−0.2%; 0.3%) after 3 years and 0.9% (0.3%; 1.2%) between 
immediate ART and giving ART if CD4 <350/15% (Figure 3, 
top right and eTable 2a; http://links.lww.com/EDE/A987). 
The trends can be seen in all age groups and regions (eTable2; 
http://links.lww.com/EDE/A987). Mortality after 3 years was 
estimated to be higher among 1- to 2-year-olds compared with 
older children (MD for immediate ART 1.3% [0.5%; 2.8%], 
Figure 3, bottom left, eTable 2b; http://links.lww.com/EDE/
A987) and in West Africa compared with Southern Africa 
(MD for immediate ART: 4.6% [2.9%; 5.9%], Figure 3, bot-
tom right and eTable2; http://links.lww.com/EDE/A987). The 
MDs between age groups and regions are mostly driven by 
the first 3 months after the first visit and remain reasonably 
stable thereafter (Figure 3, bottom panel). The sensitivity 
analyses led to similar conclusions when comparing interven-
tions, age groups, and regions (eFigures 2 and 3; http://links.
lww.com/EDE/A987). Mortality was somewhat greater when 
using the extended imputation approach, and slightly smaller 
when restricting the analysis to children with complete base-
line data.
Growth Analysis
Figure 4 (top left) demonstrates that the mean HAZ of 
surviving patients after 3 years of follow-up ranges between 
−1.92 (−2.09; −1.72; no ART) and −1.73 (−1.88; −1.50; imme-
diate ART). In comparison to immediate ART, the differences 
in mean HAZ after 3 years were estimated as −0.02 (−0.04; 
0.01; CD4 count/% threshold of 750/25%), −0.08 (−0.10; 
−0.05; threshold: 350/15%), and −0.19 (−0.25; −0.16; no 
ART; Figure 4, top right). Using the median HAZ, the prob-
ability of HAZ greater than −2 and the cumulative incidence 
of HAZ greater than −2 as outcome yield the same conclu-
sions (eFigure 4, eTable 3; http://links.lww.com/EDE/A987). 
The mean HAZ is generally lower in younger children and 
in South Africa; the differences between the age groups are, 
however, reasonably stable over time (Figure 4, bottom panel, 
eFigure 5; http://links.lww.com/EDE/A987). The sensitivity 
TABLE. 1BUJFOU$IBSBDUFSJTUJDTBU'JSTU$MJOJD7JTJU0WFSBMM	5PUBM
BOE4USBUJmFE"DDPSEJOHUP"HFBOE3FHJPO
1–2 Years 2–5 Years Southern Africa West Africa Total
Sex 1,910 (100%) 3,916 (100%) 4,392 (100%) 1,434 (100%) 5,826 (100%)
  Male 954 (50.0%) 2,026 (51.7%) 2,222 (50.6%) 758 (52.9%) 2,980 (51.2%)
Age (in years) 4,392 (100%) 1,434 (100%) 5,826 (100%)
  Median (1st; 3rd quartile) 2.6 (1.7; 3.7) 2.7 (1.8; 3.8) 2.6 (1.8; 3.8)
CD4 count 1,545 (80.9%) 3,208 (81.9%) 3,692 (84.1%) 1,061 (74.0%) 4,753 (81.6%)
  Median (1st; 3rd quartile) 790 (475; 1,196) 607 (365; 912) 646 (380; 984) 719 (433; 1,081) 662 (389; 1,011)
  >750 818 (52.9%) 1,165 (36.3%) 1,486 (40.3%) 497 (46.8%) 1,983 (41.7%)
CD4% 1,384 (72.5%) 2,775 (70.9%) 3,409 (77.6%) 750 (52.3%) 4,159 (71.4%)
  Median (1st; 3rd quartile) 16% (11%; 22%) 16% (10%; 23%) 16% (11%; 23%) 16% (10%; 22%) 16% (11%; 23%)
  >25% 242 (17.5%) 507 (18.3%) 633 (18.6%) 116 (15.5%) 749 (18.0%)
WAZ 1,446 (75.7%) 2,914 (74.4%) 3,766 (85.8%) 594 (41.4%) 4,360 (74.8%)
  Median (1st; 3rd quartile) −1.9 (−3.2; −0.8) −1.4 (−2.4; −0.6) −1.5 (−2.6; −0.6) −1.9 (−3.2; −0.9) −1.5 (−2.7; −0.6)
  <−2 700 (48.4%) 981 (33.7%) 1,397 (37.1%) 284 (47.8%) 1,681 (38.6%)
HAZ 1,092 (57.2%) 2,387 (61.0%) 2,972 (67.7%) 507 (35.4%) 3,479 (59.7%)
  Median (1st; 3rd quartile) −2.6 (−3.8; −1.5) −2.5 (−3.4; −1.5) −2.6 (−3.6; −1.6) −2.1 (−3.1; −1.0) −2.5 (−3.5; −1.5)
  <−2 703 (64.4%) 1,504 (63.0%) 1,929 (64.9%) 278 (54.8%) 2,207 (63.4%)
Region 1,910 (100%) 3,916 (100%) 5,826 (100%)
  West Africa 452 (23.7%) 982 (25.1%) 1,434 (24.6%)
Ever started ART 1,910 (100%) 3,916 (100%) 4,392 (100%) 1,434 (100%) 5,826 (100%)
  Yes 1,421 (74.4%) 2,936 (75.0%) 3,318 (75.6%) 1,039 (72.5%) 4,357 (74.8%)
Available data are given in absolute numbers (percentages in brackets).
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analyses confirm the above findings (eFigures 6 and 7; http://
links.lww.com/EDE/A987).
The data characteristics are overall similar when com-
paring the observed data with the data simulated with g-com-
putation under the natural course scenario, i.e., under no 
intervention, although for the CD4 measurements there are 
some deviations after 1 year of follow-up (eFigure 8; http://
links.lww.com/EDE/A987). A different definition of LTFU 
led to overall similar results (eFigure9; http://links.lww.com/
EDE/A987).
DISCUSSION
Statement of Principal Findings
We found overall lower mortality and better growth 
when starting ART earlier in children ages 1–5. These dif-
ferences were very small when comparing immediate ART 
initiation with deferring ART until the CD4 threshold of 
750/25% is reached, but clearer when comparing it with the 
CD4 threshold of 350/15%. Our findings were consistent over 
age groups and regions, but mortality was estimated to be 
lower, and growth to be faster, in children ages 2–5 and in 
Southern Africa.
Strengths of the Study
This is the first implementation of g-computation to 
estimate growth differences associated with different treat-
ment initiation rules. Consistent findings from the South-
ern and West Africa regions with differences in background 
morbidity, access and standard of HIV care, patient popu-
lations, and training possibilities are reassuring in terms of 
generalizability of our results. Our findings complement other 
studies which either focused on other age groups7,14 or were 
underpowered.13
Limitations
The outcomes of children LTFU were not known. While 
censoring by drop out can be handled using g-computation, and 
we conducted sensitivity analyses using multiple imputation, it 
may be possible that those defined to be lost have a particular 
high risk of being dead. In some settings, this is known to be 
true for adults.27–29 However, in children less is known about 
0
25
50
75
100
0 1 2 3
Follow−up time (in years)
Th
re
sh
ol
d 
re
ac
he
d 
(in
 %
)
Region Southern Africa West Africa
Kaplan−Meier approach
0
25
50
75
100
0 1 2 3
Follow−up time (in years)
Th
re
sh
ol
d 
re
ac
he
d 
(in
 %
)
Region Southern Africa Western Africa
Competing risks approach
FIGURE 2. &TUJNBUFEQSPCBCJMJUZPGGBMMJOHCFMPXB$%DPVOUPGDFMMTNN3PSB$%QFSDFOUBHFPG"WJBUIF,BQMBOo
.FJFSFTUJNBUPSUIJTmHVSFJTCBTFEPODIJMESFO	GSPN4PVUIFSO"GSJDBGSPN8FTU"GSJDB
QSFTFOUJOHXJUIB$%DPVOU
PGDFMMTNN3PSBCPWFBOEB$%PGPSBCPWF0OMZQSF"35GPMMPXVQJTDPOTJEFSFEBOEMPTUPSEFBEDIJMESFOXFSF
DFOTPSFEBUUIFUJNFPGUIFSFTQFDUJWFFWFOU#"35JOJUJBUJPOEFBUIBOE-5'6XFSFUSFBUFEBTDPNQFUJOHSJTLT5IFQSPCBCJMJUZ
PGGBMMJOHCFMPXUIFUISFTIPMEXBTFTUJNBUFEWJBUIFDVNVMBUJWFJODJEFODFPGGBMMJOHCFMPXUIFUISFTIPMECFGPSFBOZPUIFSFWFOU
PDDVSSFEEJWJEFECZPOFNJOVTUIFQSPCBCJMJUZUIBUBOZPUIFSFWFOUPDDVSSFECFGPSFUIFUISFTIPMEXBTSFBDIFEDPOmEFODF
JOUFSWBMTXFSFPCUBJOFEWJBCPPUTUSBQQJOHBOEBSFWJTVBMJ[FEWJBUIFshaded area"35JOEJDBUFTBOUJSFUSPWJSBMUSFBUNFOU-5'6MPTT
UPGPMMPXVQ
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Epidemiology t 7PMVNF/VNCFS.BSDI When to Start ART in Children
© 2015 Wolters Kluwer Health, Inc. All rights reserved. XXXFQJEFNDPN ] 243
those LTFU because reasons for missing an appointment may 
relate to the caregiver’s work responsibilities, family situations, 
economic opportunities, and own health status.30 Studies that 
trace lost children or link them to vital registries are needed to 
gain more knowledge about this group. While it is possible that 
the deviations between observed CD4 data and the data gener-
ated under the natural course scenario (eFigure 8; http://links.
lww.com/EDE/A987) are due to informative censoring, unmea-
sured confounding related to clinical events not captured by 
WAZ data (i.e., encephalopathy or HIV-associated nephropa-
thy), or model misspecification, offer alternative explanations.
Our study requires children to have at least one follow-up 
visit. Children who were excluded because of no follow-up data 
had higher CD4 counts (median [first; third quartile]: 742 [422; 
1,220]) and higher CD4% (20 [13; 28]) but lower weight- and 
height-for-age z-score values (−2.3 [−3.7; −0.9] and −2.8 [−3.8; 
−1.5], respectively). This means that mortality at the popula-
tion level could potentially differ from our estimates.
We assume CD4 count/% to be measured 3 monthly and 
ART to be started instantaneously after patients become eligi-
ble under the respective treatment strategy. Our estimates are, 
therefore, obtained under idealized conditions and may not be 
directly applicable to existing conditions in sub-Saharan Africa, 
i.e., if CD4 is performed less frequently or initiation of ART is 
not instantaneous after dropping below the threshold, it is pos-
sible that mortality and growth differences between immediate 
and deferred ART would be different from our estimates. How-
ever, it is noteworthy that both the PREDICT and the CHER 
trial scheduled visits no more than 3 months apart.
Other limitations relate to the lack of long-term out-
come data and therefore the possibility of examining effects 
of toxicities and drug resistance. Also, missing data on first-
line regimens and differences in drug use between countries 
make it difficult to evaluate growth and mortality outcomes 
stratified by ART regimen. It may be possible that children on 
nevirapine show better growth outcomes compared with chil-
dren using lopinavir, but also higher virological failure which 
could result in higher mortality.31
Results in Context
While we found a trend toward higher mortality being 
associated with starting ART at lower CD4 thresholds, dif-
ferences between the criteria of starting ART immediately 
and delaying until CD4 < 750/25% were negligible, for all 
follow-up times and across regions and age groups. In line 
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with previous reports,13,14 this suggests that the change in 
WHO guidelines in 2013 may neither result in increased nor 
decreased mortality in young children. However, estimated 
mortality was higher, and growth slower, when starting ART 
at the 350/15% threshold, confirming that later ART initiation, 
as recommended in 2006, may have consequences in terms of 
both mortality and growth.
In line with the results of the PREDICT trial, where chil-
dren were enrolled with higher HAZ than in our study (mean 
HAZ −1.7 vs. −2.5), we found a better growth response related 
to early ART initiation. We could, however, show no differ-
ence related to the criteria of starting ART immediately versus 
delaying until the threshold of 750/25% is reached. An impor-
tant consideration regarding interpretation and understand-
ing of our growth results relates to the fact that at different 
time points and for different interventions a different number 
of survivors remain, and thus comparisons are difficult. How-
ever, our results from the competing risk and sensitivity analy-
ses (eTable 3, eFigure 7; http://links.lww.com/EDE/A987) 
address this concern and confirm the overall findings of the 
mean height-for-age z-score results. Moreover, our results can 
be considered as conservative estimates of the effect of earlier 
ART initiation: the number of survivors at lower ART initiation 
thresholds is overall lower with some of the sicker patients, 
with lowest height-for-age z score, thus excluded from the 
mean score when compared with higher thresholds; therefore, 
true differences between initiation criteria for any particular 
group of survivors might be larger than reported by us.
In our data, mortality was estimated to be higher in West 
Africa when compared with Southern Africa. This may relate 
to higher malnutrition in West Africa, a different background 
of coinfections, such as malaria, difficult access to care, dif-
ferent ART monitoring, and the role of stigma.32,33 However, 
these differences were largely driven by differences during the 
first 3 months after enrollment. As indicated earlier, it might 
be possible that the high proportion of lost children in the first 
3 months in Southern Africa includes a substantial proportion 
of children who died. It is still possible that some of the differ-
ences between regions can be attributed to under-ascertained 
mortality in Southern Africa.
Mortality was estimated to be higher, and growth 
slower, in children ages 1–2 compared with older children. 
This mainly reflects the differences at presentation: the 
group of children ages 1–2 contains many children who have 
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probably been infected in utero or at birth. These children tend 
to have more severe disease, with a worse survival progno-
sis: if a child is not diagnosed with HIV in early infancy, it 
may only be identified too late (i.e., when caregivers arrive at 
a health care facility with a very sick child). These children 
have a high risk of death before or shortly after presentation. 
The age group of children ages 2–5 contains fewer of these 
children because these children are more long-term survivors 
when they are 2 or older than earlier. In addition, even in the 
absence of HIV, mortality is highest in infants and declines 
with increasing age during childhood.
Further Considerations and Future Directions
Our results suggest no negative consequences regard-
ing mortality and growth response when starting ART at the 
earliest presentation to health care services in young children 
ages 1–5. There are, however, other relevant considerations for 
determining the optimal time of treatment initiation: in settings 
with limited resources and few trained health care workers the 
allocation of resources needs to be considered carefully. Rapid 
ART initiation should not happen at the expense of neglect-
ing early infant diagnosis and withholding care from the most 
vulnerable children. However, only about 11% of the children 
in our data presented with a CD4 count >750 cells/mm3 and 
CD4% >25% and about 75% of those progressed to below this 
threshold within 3 years. This suggests that the additional bur-
den of early treatment initiation may be moderate, although 
probably underestimated by us because our cohorts may not 
be representative of all HIV infected children between 1 and 
5 years old. ART also implies lifelong therapy and therefore 
early treatment goes along with longer exposure to the risks 
of nonadherence, toxicity, and resistance. It remains important 
to identify a caregiver who understands the implications and 
responsibilities of starting ART. Moreover, there may be non-
identified long-term risks and changing WHO guidelines back 
to delayed treatment may not be feasible anymore.
Nevertheless, recommending treatment initiation in all 
young children regardless of their immunological and clinical 
stage, may improve access to care, simplify pediatric treat-
ment and facilitate expansion of ART coverage. Given the 
rapid disease progression in young children, using CD4 cri-
teria may not delay the onset of therapy very much and risk 
children of dropping out of health care. Moreover, regular 
CD4 measurements are not available in all resource-limited 
settings. Early treatment initiation may also be beneficial for 
immune recovery and neurodevelopment.
CONCLUSIONS
Early treatment initiation yields better growth and mor-
tality outcomes in children ages 1 to 5 from West and South-
ern Africa, although differences between immediate ART 
initiation and delaying until CD4 <750/25% are negligible. 
Younger children had worse outcomes in our study, but future 
studies need to confirm this and address programmatic and 
long-term implications and challenges of early treatment ini-
tiation to improve their survival.
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